The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading
In a new two year clinical trial conducted by the University of Miami, researchers will attempt to treat deep second degree burn victims with mesenchymal stem cells [MSCs] as a potential alternative to skin grafts. The team, led by Dr. Evangelos Badiavas, will first cover the wounds in protective dressing, and then inject the MSCs under the dressing and into the wounds to spur the regeneration of the inner and outer layers of skin.
Severe burns currently account for 450,000 emergency room treatments annually, as well as 15-20% of combat injuries to military veterans. But despite a high demand to eliminate painful and taxing skin graft surgeries, they are currently the only option for reconstruction. While Dr. Badiavas’ stem cell therapy is in its initial assessment phase, early indications point to possible MSC treatments that may provide a more comfortable and efficient method to regenerate healthy skin tissue, resulting in better outcomes for patients.
As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™
In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading
In a new pilot study at the Royal National Orthopaedic Hospital in London, researchers will utilize stem cells to promote the healing of painful tendon injuries such as tennis elbow. Initial studies suggest that, upon transplantation, the stem cells release growth factors to the point of injury, which induce the growth of new tendon tissue while reducing scar tissue to recover movement and flexibility. Continue reading
In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells. The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well. Continue reading
Today, stem cells are rightfully perceived as the future of regenerative medicine, set to bring the marvels of science fiction into reality. But in looking ahead at all of the promise that stem cells hold for the future, it becomes easy to miss the scientific advances made to date for the millions of people around the world suffering from disease, trauma, and injury. Thus, today marks Stem Cell Awareness Day: a global celebration of stem cell research coordinated to highlight the treatments and therapies currently in development to create personalized regenerative therapies for patients. Continue reading
A recent study presented at the European Respiratory Society’s International Congress has developed a possible treatment for Acute Respiratory Distress Syndrome (ARDS) by using Mesenchymal Stem Cells [MSC] to reduce inflammation in the lungs. In an animal model, stem cells released proteins that stimulate macrophages (a type of white blood cell) to suppress the excessive immune response that can severely damage a patient’s lungs. Continue reading
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas. Continue reading
In recent clinical trials, researchers at the National University of Ireland Galway have successfully utilized adult stem cells to treat patients with osteoarthritis. The treatment involves recovering the patients’ own [autologous] stem cells and then injecting the stem cells into cartilage to stimulate the regeneration of lost tissue. Continue reading
Researchers at the Cedars-Mt. Sinai Regenerative Medicine Institute, led by Dr. Robert H. Baloh, have devised a method to study and develop potential treatments for Amyotrophic Lateral Sclerosis [ALS] by utilizing patients’ stem cell-derived neurons. In an example of what is referred to as translational genomics, researchers extract autologous (the patient’s own) stem cells, correct the defective gene causing the disease, and then, in a potential treatment protocol, transplant the cells back into the patient to reverse neural degeneration. Continue reading